Skip to main content
Arlene Nugent

Arlene Nugent


Scientific Director Specialty Pipeline, AbbVie
Canada


Arlene Nugent joined AbbVie in 2014, becoming part of the Canadian virology team with a focus on the established HIV franchise, and was also a member of the hepatitis C direct-acting antivirals medical team. She played a pivotal role in the oncology solid tumours pipeline as the Medical Affairs Lead in Canada before returning to the virology team. In 2020, Arlene transitioned to the newly established global medical specialty pipeline team as a Scientific Director, where she focused on COVID-19 and HIV viral control off-ART development. Throughout her time at AbbVie, she has been actively involved in numerous initiatives, including protocol development for clinical trials, the healthcare client engagement team and the culture club.

Arlene has 25 years of industry experience, having previously worked at Genzyme and Eisai. She completed her Master’s degree in human biology in Canada, with a specialization in the control of metabolic diseases. Additionally, she studied health services research as part of a PhD programme.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.